RESEARCH · GLOW BLEND · TB-500 / Tβ4
GLOW BLEND Components and Thymosin β4: Actin Sequestration, Angiogenesis and What Each Peptide Contributes
PurixLab’s GLOW BLEND 70mg combines three research materials often discussed together: BPC-157, TB-500 (a research designation tied to thymosin β4 sequences) and GHK-Cu. Our earlier overview, GLOW BLEND 70mg: what the research says about BPC-157, TB-500 and GHK-Cu, sketched each component. This article goes deeper on the best-characterised molecular story in the set — thymosin β4 as an actin-sequestering peptide — and then compares, side by side, what peer-reviewed work actually shows for each ingredient. The blend and its components are supplied for laboratory research use only.
Thymosin β4: from thymus fraction to actin buffer
Thymosin β4 began as a peptide purified from thymic extracts. The decisive biochemical finding came when Safer and colleagues showed that the platelet actin-sequestering peptide they had named Fx was indistinguishable from thymosin β4: at least 50% of the actin in resting human platelets is unpolymerised, and the bulk of that pool is complexed with this acidic, heat-stable ~5 kDa peptide [1]. In living epithelial cells and fibroblasts, raising intracellular thymosin β4 by microinjection diminished stress fibres and depolymerised actin filaments in a concentration-dependent way [2].
Quantitative binding work later placed both thymosin β4 and its major homolog thymosin β10 as monomeric G-actin sequesterers with similar dissociation constants, between 0.7 and 1 μM, without inhibition by polyphosphoinositides [3]. Reviews summarise the current picture: β-thymosins are the main intracellular G-actin-sequestering peptides in most vertebrate cells; the peptide is unstructured in solution and folds on binding actin, with a micromolar dissociation constant that allows rapid binding and release [4,5]. Only the cytoskeletal interaction has a clear molecular explanation; other attributed activities still lack comparable mechanistic maps [5,4].
From G-actin pools to migration and vessel models
Because free G-actin availability gates filament assembly, sequestering peptides sit upstream of cell shape and motility. In vitro and in vivo migration assays showed that thymosin β4 acts as a chemoattractant for human umbilical vein endothelial cells, stimulating migration in Boyden chambers four- to sixfold over medium alone; of primary cell types tested, coronary-artery cells were among those that responded [6]. The polypeptide is described as about 4.9 kDa in that work [6].
Preclinical dermal and ocular programmes then tested whether those cytoskeletal and migratory effects translate into tissue repair readouts. Reviews report that thymosin β4 increased the rate of dermal healing in animal models, including diabetic and aged animals, and accelerated re-epithelialisation, while ocular work emphasises anti-inflammatory and epithelial-healing signals in the cornea [7,8]. Those are animal and cell findings; they are not clinical proof for a finished drug product, and later ocular development programmes mentioned in narrative reviews are outside the scope of the molecular papers summarised here [7].
Component comparison: three different evidence stacks
GLOW BLEND is a mixture, so it helps to keep the evidence lines separate rather than treating the blend as a single studied entity.
- TB-500 / thymosin β4. Strongest molecular footing: stoichiometric G-actin binding, measured Kd values, and endothelial migration assays [1,3,6]. Extracellular cytokine-like claims remain mechanistically thinner [4].
- BPC-157. Preclinical papers emphasise angiomodulation. In muscle and tendon injury models, immunohistochemical markers (VEGF, CD34, FVIII) were consistent with modulated angiogenesis during healing, yet the same group reported no direct angiogenic effect in cell culture alone [9]. Separate work links BPC-157 to VEGFR2 activation, internalisation and Akt–eNOS signalling in endothelial models, and to faster alkali-burn wound closure with higher VEGF expression in rats [10,11]. Almost no controlled human trials exist for BPC-157; that gap is discussed in our preclinical versus human-data article.
- GHK-Cu. The copper(II)–tripeptide complex has a long fibroblast and wound-model record: stimulation of collagen synthesis in culture, broad tissue-remodelling gene programmes, and many cosmetic or topical reports [12,13,14]. Delivery and speciation questions are covered in our GHK-Cu delivery article.
What a blend study would still need
- No blend pharmacokinetics. We did not find peer-reviewed ADME or interaction studies on a BPC-157 + TB-500 + GHK-Cu mixture that match this commercial format.
- Attribution. When carriers, scaffolds or injury models are themselves bioactive, effects cannot be assigned to one peptide alone [11,7].
- Intact molecule versus fragment. Actin-binding explains intracellular sequestration; how much intact peptide survives extracellular experimental systems is often unmeasured [4].
- Human data imbalance. GHK-Cu has small cosmetic/clinical series; thymosin β4 has ocular development history; BPC-157 remains almost entirely preclinical [14,7,9].
GLOW BLEND 70mg at PurixLab
GLOW BLEND 70mg: a labelled lyophilized research vial combining BPC-157, TB-500 and GHK-Cu (70mg labelled content per vial), C$136 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/glow-blend-70mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-32. PubMed 1999398
- Sanders MC, Goldstein AL, Wang YL. Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proc Natl Acad Sci U S A. 1992;89(10):4678-82. PubMed 1584803 · PMC49146 · doi:10.1073/pnas.89.10.4678
- Yu FX, Lin SC, Morrison-Bogorad M, et al. Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins. J Biol Chem. 1993;268(1):502-9. PubMed 8416954
- Hannappel E. beta-Thymosins. Ann N Y Acad Sci. 2007;1112:21-37. PubMed 17468232 · doi:10.1196/annals.1415.018
- Bubb MR. Thymosin beta 4 interactions. Vitam Horm. 2003;66:297-316. PubMed 12852258 · doi:10.1016/s0083-6729(03)01008-2
- Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474-81. PubMed 9194528 · doi:10.1096/fasebj.11.6.9194528
- Kleinman HK, Sosne G. Thymosin β4 Promotes Dermal Healing. Vitam Horm. 2016;102:251-75. PubMed 27450738 · doi:10.1016/bs.vh.2016.04.005
- Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta-4 and the eye: I can see clearly now the pain is gone. Ann N Y Acad Sci. 2007;1112:114-22. PubMed 17495249 · doi:10.1196/annals.1415.004
- Brcic L, Brcic I, Staresinic M, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009;60 Suppl 7:191-6. PubMed 20388964
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. PubMed 27847966 · doi:10.1007/s00109-016-1488-y
- Huang T, Zhang K, Sun L, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485-99. PubMed 25995620 · PMC4425239 · doi:10.2147/DDDT.S82030
- Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. PubMed 3169264 · doi:10.1016/0014-5793(88)80509-x
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-88. PubMed 18644225 · doi:10.1163/156856208784909435
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PubMed 26236730 · PMC4508379 · doi:10.1155/2015/648108